Delirium affects many hospitalized older Australians, and while it can have many complications, treatments are limited.
Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback